Independent analysis of where medical tourism helps patients and where it fails them — and plain-language guides that include the parts bad for our business: when a second opinion is unnecessary, and when travelling for treatment is the wrong call.
First-party analysis on the economics, ethics and safety of cross-border care.
India's medical arrivals fell in 2025 and two-thirds came from one neighbour. Scaling twentyfold means winning patients who have choices — and they buy confidence, not discounts.
When medical advice and the business of arranging treatment are financially connected, who gets paid for telling a patient not to travel? The case for independent second opinions.
As patients cross borders for cancer, cardiac and complex care, travel coordination is no longer enough. Patients need clinical decision support before they leave and continuity after they return.
US health-benefit costs are set to rise the most since 2003, and employers plan to pass it on. That changes who counts as a price-sensitive patient — before the safety infrastructure exists.
The industry measures how many patients travel and how much they save. A patient-first industry would measure how many people were helped to make the right decision — even when that meant not travelling.
The CDC documented what happens when care ends at the airport. The EU legislated the infrastructure to prevent it — and left a door open for third countries. The industry hasn't walked through it.
The CDC reviewed a decade of its own consultations and called for stronger surveillance. Until it exists, the only protection is upstream: an independent answer to whether the procedure is warranted at all.
Two competent specialists can read the same file and reach different conclusions. That is not malpractice — it is how clinical medicine works. Here is why, and where it matters most.
US$100 internationally, ₹3,500–₹7,500 domestically. What is included at each price, and what the cheaper options leave out.
A remote reviewer cannot palpate an abdomen or test a reflex. For most second-opinion questions that does not matter. For some it decides everything.
Staging, molecular subtype, and operability are the three places oncologists most often disagree. What to send, and the questions that get useful answers.
No — and a doctor who makes it difficult has told you something useful. How to ask, and what you are entitled to.
Teleconsultation is permitted, regulated, and has specific limits. What a doctor may and may not do over video, and what you should check before booking.
We advise against travel in a meaningful share of the cases we review. These are the situations where staying home is the better clinical decision.
Indicative estimates are not quotes. How overruns actually get handled, and the specific wording to look for in an agreement.
Where the difference is real, what published figures do and do not include, and why the headline saving is rarely the number you end up paying.
Accreditation measures process, not surgeon skill. What it tells you, what it does not, and what to ask beyond the certificate.
Eligibility, the hospital invitation letter, the attendant visa for a companion, and the errors that cause most rejections.
Documents, medication, DVT risk on the return leg, and the conversation to have with your own doctor before you go.
The cost of waiting is clinical as well as financial. What to arrange with your GP before and after, and where going abroad backfires.
Who comes, for what, what genuinely works well, and the four failure modes that account for most bad experiences.
Independent media coverage of Healing Tourist and the "second opinion before travel" approach.